Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND)
Today, Credit Suisse Group raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to $86.00 per share.
There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy with a consensus target price of $78.25 per share, a potential 20.72% upside.
Some recent analyst ratings include
- 8/7/2018-Ascendis Pharma A/S (NASDAQ:ASND) has coverage initiated with a Buy rating and $81.00 price target
- 5/31/2018-Ascendis Pharma A/S (NASDAQ:ASND) had its Market Perform rating reiterated by Leerink Swann with a $70.00 price target
About Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Recent Trading Activity for Ascendis Pharma A/S (NASDAQ:ASND)
Shares of Ascendis Pharma A/S closed the previous trading session at 65,25 up +4,15 6,79 % with 67 shares trading hands.